139 related articles for article (PubMed ID: 31012515)
1. Indoleamine 2, 3-dioxygenase 1 promoter hypomethylation is associated with poor prognosis in patients with esophageal cancer.
Kiyozumi Y; Baba Y; Okadome K; Yagi T; Ogata Y; Eto K; Hiyoshi Y; Ishimoto T; Iwatsuki M; Iwagami S; Miyamoto Y; Yoshida N; Watanabe M; Baba H
Cancer Sci; 2019 Jun; 110(6):1863-1871. PubMed ID: 31012515
[TBL] [Abstract][Full Text] [Related]
2. DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients' survival, immune cell infiltrates, mutational load, and interferon γ signature.
Sailer V; Sailer U; Bawden EG; Zarbl R; Wiek C; Vogt TJ; Dietrich J; Loick S; Grünwald I; Toma M; Golletz C; Gerstner A; Kristiansen G; Bootz F; Scheckenbach K; Landsberg J; Dietrich D
EBioMedicine; 2019 Oct; 48():341-352. PubMed ID: 31628024
[TBL] [Abstract][Full Text] [Related]
3. Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers.
Noonepalle SK; Gu F; Lee EJ; Choi JH; Han Q; Kim J; Ouzounova M; Shull AY; Pei L; Hsu PY; Kolhe R; Shi F; Choi J; Chiou K; Huang TH; Korkaya H; Deng L; Xin HB; Huang S; Thangaraju M; Sreekumar A; Ambs S; Tang SC; Munn DH; Shi H
Cancer Immunol Res; 2017 Apr; 5(4):330-344. PubMed ID: 28264810
[TBL] [Abstract][Full Text] [Related]
4. IDO1 Expression Is Associated With Immune Tolerance and Poor Prognosis in Patients With Surgically Resected Esophageal Cancer.
Kiyozumi Y; Baba Y; Okadome K; Yagi T; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Komohara Y; Baba H
Ann Surg; 2019 Jun; 269(6):1101-1108. PubMed ID: 31082908
[TBL] [Abstract][Full Text] [Related]
5. Changes in Indoleamine 2,3-Dioxygenase 1 Expression and CD8+ Tumor-Infiltrating Lymphocytes after Neoadjuvant Chemoradiation Therapy and Prognostic Significance in Esophageal Squamous Cell Carcinoma.
Zhou S; Yang H; Zhang J; Wang J; Liang Z; Liu S; Li Y; Pan Y; Zhao L; Xi M
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):286-294. PubMed ID: 32004580
[TBL] [Abstract][Full Text] [Related]
6. Indoleamine-2,3-dioxygenase-1 expression predicts poorer survival and up-regulates ZEB2 expression in human early stage bladder cancer.
Tsai YS; Jou YC; Tsai HT; Cheong IS; Tzai TS
Urol Oncol; 2019 Nov; 37(11):810.e17-810.e27. PubMed ID: 31253481
[TBL] [Abstract][Full Text] [Related]
7. Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma.
Kozuma Y; Takada K; Toyokawa G; Kohashi K; Shimokawa M; Hirai F; Tagawa T; Okamoto T; Oda Y; Maehara Y
Eur J Cancer; 2018 Sep; 101():20-29. PubMed ID: 30014971
[TBL] [Abstract][Full Text] [Related]
8. Methylation-mediated repression of potential tumor suppressor miR-203a and miR-203b contributes to esophageal squamous cell carcinoma development.
Liu Y; Dong Z; Liang J; Guo Y; Guo X; Shen S; Kuang G; Guo W
Tumour Biol; 2016 Apr; 37(4):5621-32. PubMed ID: 26577858
[TBL] [Abstract][Full Text] [Related]
9. Mechanism and prognostic value of indoleamine 2,3-dioxygenase 1 expressed in hepatocellular carcinoma.
Li S; Han X; Lyu N; Xie Q; Deng H; Mu L; Pan T; Huang X; Wang X; Shi Y; Zhao M
Cancer Sci; 2018 Dec; 109(12):3726-3736. PubMed ID: 30264546
[TBL] [Abstract][Full Text] [Related]
10. Hypermethylation of the nel-like 1 gene is a common and early event and is associated with poor prognosis in early-stage esophageal adenocarcinoma.
Jin Z; Mori Y; Yang J; Sato F; Ito T; Cheng Y; Paun B; Hamilton JP; Kan T; Olaru A; David S; Agarwal R; Abraham JM; Beer D; Montgomery E; Meltzer SJ
Oncogene; 2007 Sep; 26(43):6332-40. PubMed ID: 17452981
[TBL] [Abstract][Full Text] [Related]
11. 5-Azacytidine suppresses EC9706 cell proliferation and metastasis by upregulating the expression of SOX17 and CDH1.
Li W; Wu D; Niu Z; Jiang D; Ma H; He H; Zuo X; Xie X; He Y
Int J Mol Med; 2016 Oct; 38(4):1047-54. PubMed ID: 27513557
[TBL] [Abstract][Full Text] [Related]
12. Hypomethylation of the protein gene product 9.5 promoter region in gallbladder cancer and its relationship with clinicopathological features.
Lee YM; Lee JY; Kim MJ; Bae HI; Park JY; Kim SG; Kim DS
Cancer Sci; 2006 Nov; 97(11):1205-10. PubMed ID: 16965602
[TBL] [Abstract][Full Text] [Related]
13. LINE-1 hypomethylation is associated with a poor prognosis among patients with curatively resected esophageal squamous cell carcinoma.
Iwagami S; Baba Y; Watanabe M; Shigaki H; Miyake K; Ishimoto T; Iwatsuki M; Sakamaki K; Ohashi Y; Baba H
Ann Surg; 2013 Mar; 257(3):449-55. PubMed ID: 23023202
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic inactivation of SPINT2 is associated with tumor suppressive function in esophageal squamous cell carcinoma.
Yue D; Fan Q; Chen X; Li F; Wang L; Huang L; Dong W; Chen X; Zhang Z; Liu J; Wang F; Wang M; Zhang B; Zhang Y
Exp Cell Res; 2014 Mar; 322(1):149-58. PubMed ID: 24269829
[TBL] [Abstract][Full Text] [Related]
15. Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer.
Dewi DL; Mohapatra SR; Blanco Cabañes S; Adam I; Somarribas Patterson LF; Berdel B; Kahloon M; Thürmann L; Loth S; Heilmann K; Weichenhan D; Mücke O; Heiland I; Wimberger P; Kuhlmann JD; Kellner KH; Schott S; Plass C; Platten M; Gerhäuser C; Trump S; Opitz CA
Oncoimmunology; 2017; 6(2):e1274477. PubMed ID: 28344890
[TBL] [Abstract][Full Text] [Related]
16. Lysyl oxidase impacts disease outcomes and correlates with global DNA hypomethylation in esophageal cancer.
Kalikawe R; Baba Y; Nomoto D; Okadome K; Miyake K; Eto K; Hiyoshi Y; Nagai Y; Iwatsuki M; Ishimoto T; Iwagami S; Miyamoto Y; Yoshida N; Watanabe M; Baba H
Cancer Sci; 2019 Dec; 110(12):3727-3737. PubMed ID: 31599475
[TBL] [Abstract][Full Text] [Related]
17. Promoter hypermethylation-mediated downregulation of tumor suppressor gene SEMA3B and lncRNA SEMA3B-AS1 correlates with progression and prognosis of esophageal squamous cell carcinoma.
Dong Z; Liang X; Wu X; Kang X; Guo Y; Shen S; Liang J; Guo W
Clin Exp Metastasis; 2019 Jun; 36(3):225-241. PubMed ID: 30915595
[TBL] [Abstract][Full Text] [Related]
18. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer.
Ogishima T; Shiina H; Breault JE; Tabatabai L; Bassett WW; Enokida H; Li LC; Kawakami T; Urakami S; Ribeiro-Filho LA; Terashima M; Fujime M; Igawa M; Dahiya R
Clin Cancer Res; 2005 Feb; 11(3):1028-36. PubMed ID: 15709168
[TBL] [Abstract][Full Text] [Related]
19.
Gonzaga IM; Soares Lima SC; Nicolau MC; Nicolau-Neto P; da Costa NM; de Almeida Simão T; Hernandez-Vargas H; Herceg Z; Ribeiro Pinto LF
Clin Epigenetics; 2017; 9():130. PubMed ID: 29296124
[TBL] [Abstract][Full Text] [Related]
20. Identification of the novel Ido1 imprinted locus and its potential epigenetic role in pregnancy loss.
Spinelli P; Latchney SE; Reed JM; Fields A; Baier BS; Lu X; McCall MN; Murphy SP; Mak W; Susiarjo M
Hum Mol Genet; 2019 Feb; 28(4):662-674. PubMed ID: 30403776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
